Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is ‘rapidly advancing B cell-based therapeutics.’ Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.
‘We are delighted to partner with Walking Fish to help advance their B cell platform and support their innovative approach to develop novel therapies for the treatment of serious diseases,’ says Chief Executive Officer Doug Doerfler.
Current stock price: 370.00 pence, down 3.9% in London on Thursday
12-month change: down 15%
Copyright 2023 Alliance News Ltd. All Rights Reserved.